Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 16, Issue 5, Pages 647-691Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.16.5.647
Keywords
antitubulin; kinesin-like spindle protein inhibitor; medicinal chemistry; microtubule-destabilising agent; microtubule-stabilising agent
Categories
Ask authors/readers for more resources
The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available